Sirotnak F M, Barrueco J R
Laboratory for Molecular Therapeutics, Memorial Sloan-Kettering Cancer Center, New York, N.Y. 10021.
Cancer Metastasis Rev. 1987;6(4):459-80. doi: 10.1007/BF00047462.
This article summarizes recent studies characterizing nucleoside transport in mammalian cells and discusses evidence for a role of membrane transport in the pharmacologic action of nucleoside analogues. Some of these studies have also addressed the controversy concerning the multiplicity in transport routes. It seems clear that erythrocytes and, perhaps, some other mammalian cells possess a single, broadly specific system for transporting nucleosides. However, substantial evidence from valid studies discriminating between transport and intracellular metabolism suggests that at least some mammalian cells, including some tumor cells, possess more than a single system. Evidence now exists for a determining role of membrane transport of nucleoside analogues in their cytotoxicity and, in the case of one pyrimidine nucleoside (AraC), in therapeutic responsiveness in leukemic patients. There are also numerous examples of transport-related resistance to nucleoside analogues. Included in this article are the results of studies from the authors' laboratory pertaining to the therapeutic activity of the purine nucleoside, FAraA, in murine tumor models. These studies provide evidence for a determining role of both membrane transport and intracellular phosphorylation in the selective antitumor action of this agent against murine leukemia. Substantially increased transport inward of FAraA occurs at pharmacologically achievable concentrations of this agent in tumor cells as compared to drug-limiting, normal proliferative epithelium of the small intestine. The basis for this differential appears to be the kinetic duality of FAraA and adenosine transport inward found in tumor cells, but not in proliferative intestinal epithelial cells. Tumor cells have highly saturable (low influx Km) and poorly saturable (high influx Km) systems for adenosine transport, both of which are shared by FAraA. In contrast, proliferative epithelial cells have only a poorly saturable system for these substrates. If a similar kinetic duality of nucleoside transport is found in other tumor cells certain implications arise concerning the significance of the duality to neoplastic transformation.
本文总结了近期关于哺乳动物细胞中核苷转运特征的研究,并讨论了膜转运在核苷类似物药理作用中发挥作用的证据。其中一些研究还探讨了有关转运途径多样性的争议。很明显,红细胞以及或许其他一些哺乳动物细胞拥有单一的、具有广泛特异性的核苷转运系统。然而,来自区分转运与细胞内代谢的有效研究的大量证据表明,至少一些哺乳动物细胞,包括一些肿瘤细胞,拥有不止一种转运系统。现在有证据表明核苷类似物的膜转运在其细胞毒性中起决定性作用,对于一种嘧啶核苷(阿糖胞苷)而言,在白血病患者的治疗反应中也起决定性作用。也有许多与核苷类似物转运相关的耐药例子。本文包含了作者实验室关于嘌呤核苷氟阿糖腺苷(FAraA)在小鼠肿瘤模型中治疗活性的研究结果。这些研究为膜转运和细胞内磷酸化在该药物对小鼠白血病的选择性抗肿瘤作用中起决定性作用提供了证据。与小肠药物限量的正常增殖上皮相比,在该药物药理学可达到的浓度下,肿瘤细胞中FAraA的内向转运显著增加。这种差异的基础似乎是肿瘤细胞中发现的FAraA和腺苷内向转运的动力学双重性,而在增殖性肠上皮细胞中未发现。肿瘤细胞具有高度可饱和(低流入Km)和低可饱和(高流入Km)的腺苷转运系统,FAraA均可利用这两种系统。相比之下,增殖上皮细胞对于这些底物只有一个低可饱和系统。如果在其他肿瘤细胞中发现类似的核苷转运动力学双重性,那么这种双重性对肿瘤转化的意义就会产生某些影响。